Human epidermal growth factor receptor 2 expression level and combined positive score can evaluate efficacy of advanced gastric cancer

Table 1 Baseline characteristics, n (%)

Variable	All (63)	Excellent efficacy group (42)	Poor efficacy group (21)
Age	56 (51, 58)	56 (50, 58)	59 (50, 62)
Sex
Male	34 (54.7)	20 (47.6)	14 (66.7)
Female	29 (45.3)	22 (52.4)	7 (33.3)
ECOG-PS
0	17 (27.0)	12 (28.6)	5 (23.8))
1	39 (61.9)	26 (61.9)	13 (61.9)
2	7 (11.1)	4 (9.5)	3 (14.3)
Disease status
Unresectable	55 (87.3)	38 (90.5)	17 (81.0)
Recurrent	8 (12.7)	4 (9.5)	4 (19.0)
Number of organs involved
1	40 (63.5)	27 (64.3)	13 (61.9)
≥ 2	23 (36.5)	15 (35.7)	8 (38.1)
HER2 status
0	31 (49.2)	17 (40.5)	14 (66.7)
1	15 (23.8)	10 (23.8)	5 (23.8)
2	11 (17.5)	11 (26.2)	0 (0)
Unmeasured	6 (9.5)	4 (9.5)	2 (9.5)
CPS
0	8 (12.7)	2 (4.8)	6 (28.6)
1 ≤ CPS < 5	11 (17.5)	7 (16.7)	4 (19.0)
5 ≤ CPS < 10	12 (19.0)	9 (21.4)	3 (14.3)
CPS ≥ 10	21 (33.3)	18 (42.9)	3 (14.3)
Unmeasured	11 (17.5)	6 (14.3)	5 (23.8)
EBER
Positive	7 (11.1)	6 (14.3)	1 (4.8)
Negative	42 (66.7)	26 (61.9)	16 (76.2)
Unmeasured	14 (22.2)	10 (23.8)	4 (19.0)

ECOG-PS: Eastern cooperative oncology group-performance status; CPS: Combined positive score; HER2: Human epidermal growth factor receptor 2; EBER: Epstein-Barr virus-encoded small RNA.

Table 2 Best overall response (patients with measurable lesions)

	Group A (N = 42)		Group B (N = 21)		P value
	n (%)	95%CI	n (%)	95%CI
Best overall response
Complete response (CR)	0	-	0	-	-
Partial response (PR)	30 (71.4)	-	9 (42.9)	-	-
Stable disease (SD)	12 (28.6)	-	10 (47.6)	-	-
Progressive disease	0 (0)	-	2 (9.5)	-	-
Overall response rate (CR + PR)	30 (71.4)	55.4-84.3	9 (42.9)	21.8-66.0	0.03
Disease control rate (CR + PR + SD)	42 (100)	91.6-1.00	19 (90.5)	69.6-98.8	2.527e-13

N: The total number of subjects in the treatment group. It is the denominator for percentage (%) calculation. n: Number of subjects who are at the corresponding category. The exact 95%CI for the frequency distribution of each variable were computed using Clopper and Pearson method.